Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-CVAD + Venetoclax in Pediatric Relapsed/Refractory Acute Leukemias
NCT06466395Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax in acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL) and acute undifferentiated leukemia (AML-M0) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)acute undifferentiated leukemia (AML-M0)
Beyond the preview
Go deeper on NCT06466395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06466395.